目前公司各项经营活动和业务均正常开展。在立案调查期间，公司将积极配合证监会的相关调查工作， 并严格按照相关法律法规和监管要求及时履行信息披露义务。 1月6日晚间，英集芯曾发布关于上证E互动平台有关问题回复的说明公告。英集芯称，公司于2026年1 月6日在上证E互动平台就投资者"脑机接口"相关问题作出回复，为保障广大投资者的合法权益，公司就 相关业务情况补充说明。 公司与参股公司精芯唯尔（常州）电子科技有限公司（简称"精芯唯尔"）共同推出的IPA1299是一款支 持8通道低噪声设计，24位同步采样模数转换器芯片（ADC），主要应用于脑电图（EEG）、心电图 （ECG）和肌电图（EMG）， 该产品主要特点在于可实现高精度信号采集功能，可应用于非侵入式脑 机接口领域。该产品用于人体生物电信号的高精度测量，其适用于各种可穿戴式设备应用场景，技术路 线与当前国际上的侵入式脑机接口存在显著技术路径差异。截至公告披露日，该产品在非侵入式脑机接 口领域尚处于市场培育期，尚未实现规模化销售，暂未对公司业绩产生重大影响，未来销售情况存在不 确定性。 登录新浪财经APP 搜索【信披】查看更多考评等级 据证监会网站2月13日消息，2 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 【导读】证监会对英集芯相关信息披露涉嫌误导性陈述立案调查 中国基金报记者 晨曦 又有上市公司被立案调查！ 2月13日，证监会官网发布消息称，证监会对英集芯相关信息披露涉嫌误导性陈述立案调查。 证监会指出，2026年1月6日，深圳英集芯科技股份有限公司在上证E互动平台人为策划"自问自答"，信息披露构成误导性陈述。近日，证监会已对英集芯 立案调查。下一步，将在全面调查的基础上依法处理，切实维护市场健康发展。 英集芯表示，目前公司各项经营活动和业务均正常开展。在立案调查期间，公司将积极配合证监会的相关调查工作，并严格按照相关法律法规和监管要求 及时履行信息披露义务。 公开信息显示，有投资者在上证E互动上向英集芯提问："当前脑机接口市场关注度显著提升，看公司官网有应用于人体生物电信号领域的产品，希望公 司能把握这一机遇。能介绍一下公司在脑电信号采集等核心芯片方面的产品进展与后续规划吗？" 对于该问题，1月6日下午，英集芯回复称：公司通过早期投资布局，已涉足脑机接口芯片领域。公司推出的IPA1299是一款8通道、低噪声24位ADC芯 片，专用于人体生物电信号的高精度测量 ...

Market Analysis - The A-share market experienced a volume contraction and adjustment on the last trading day before the Spring Festival, with the Shanghai Composite Index falling by 1.26% to 4082.07 points, below the 4100-point mark [4] - The Shenzhen Component Index decreased by 1.28% to 14100.19 points, while the ChiNext Index dropped by 1.57% to 3275.96 points, indicating a broad market decline with 3824 stocks falling and only 1537 rising [4] - For the entire year, the Shanghai Composite Index rose by 25.28%, the Shenzhen Component Index by 38.84%, and the ChiNext Index by 58.73% [4] Sector Performance - The defense and military sector was the only one to gain, up 0.46%, driven by advancements in commercial aerospace technology and geopolitical tensions [6] - Semiconductor equipment index rose by 1.65%, benefiting from increased demand for storage chips and AI computing power [6] - The non-ferrous metals sector saw a significant decline of 3.31%, influenced by fluctuations in international precious metal prices [6] Bond Market - The bond futures market showed mixed performance, with the 30-year main contract rising by 0.04% to 112.84 yuan, while the 10-year contract fell by 0.10% to 108.505 yuan [8] - The central bank conducted a net injection of 613.5 billion yuan, leading to a significant decline in short-term interest rates [8] - The market is expected to remain confident in the central bank's moderately loose monetary policy, which may support bond market recovery [8] Commodity Market - The commodity index fell by 1.69%, with industrial products leading the decline, particularly in precious metals and energy [8] - The main crude oil contract dropped by 4.22% to 456.3 yuan per barrel, amid concerns over supply surplus [8] - Soybean prices surged to a one-year high, driven by supply-demand factors and weather conditions in Brazil [8] Investment Opportunities - The report suggests a balanced allocation in technology and consumer sectors, with a focus on sectors like photovoltaic technology, commercial aerospace, and non-ferrous metals for future growth [8][12] - The report highlights several hot investment themes, including AI applications, commercial aerospace, nuclear fusion, quantum technology, brain-machine interfaces, and robotics, indicating strong future potential [10][12]

英集芯表示，该产品用于人体生物电信号的高精度测量，其适用于各种可穿戴式设备应用场景，技术路 线与当前国际上的侵入式脑机接口存在显著技术路径差异。截至本公告披露日，该产品在非侵入式脑机 接口领域尚处于市场培育期，尚未实现规模化销售，暂未对公司业绩产生重大影响，未来销售情况存在 不确定性。 据悉，1月6日，英集芯在上证e互动平台回复提问称，公司通过早期投资布局，已涉足脑机接口芯片领 域。英集芯表示，公司推出的IPA1299是一款8通道、低噪声24位ADC芯片，专用于人体生物电信号的 高精度测量，可适用于脑电信号采集等脑机接口相关场景。IPA1299芯片已量产出货，性能参数可媲美 海外头部芯片产品。 当日晚间，上交所紧急向英集芯下发监管工作函，处理事由为关于深圳英集芯科技股份有限公司E互动 回复内容的监管工作函。 1月7日早间，英集芯公告称，其IPA1299芯片系与参股公司精芯唯尔（常州）电子科技有限公司共同推 出，是一款支持8通道低噪声设计，24位同步采样模数转换器芯片（ADC），主要应用于脑电图 （EEG）、心电图（ECG）和肌电图（EMG），该产品主要特点在于可实现高精度信号采集功能，可 应用于非侵入式脑机接 ...

1月7日早间，英集芯公告称， 其IPA1299芯片系与参股公司精芯唯尔（常州）电子科技有限公司共同 推出，是一款支持8通道低噪声设计，24位同步采样模数转换器芯片（ADC），主要应用于脑电图 （EEG）、心电图（ECG）和肌电图（EMG），该产品主要特点在于可实现高精度信号采集功能，可 应用于非侵入式脑机接口领域。 2月13日，证监会公告，2026年1月6日，深圳英集芯科技股份有限公司（简称英集芯）在上证E互动 平台人为策划"自问自答"，信息披露构成误导性陈述。近日，证监会已对英集芯立案调查。 下一步，证监会将在全面调查的基础上依法处理，切实维护市场健康发展。 据悉，1月6日，英集芯在 上证e互动平台回复提问称 ，公司通过早期投资布局，已涉足脑机接口芯片 领域。英集芯表示， 公司推出的IPA1299是一款8通道、低噪声24位ADC芯片，专用于人体生物电信 号的高精度测量，可适用于脑电信号采集等脑机接口相关场景。IPA1299芯片已量产出货，性能参数 可媲美海外头部芯片产品。 当日晚间，上交所紧急向英集芯下发监管工作函，处理事由为关于深圳英集芯科技股份有限公司E互动 回复内容的监管工作函。 英集芯表示， 该产品 ...

证监会对英集芯相关信息披露涉嫌误导性陈述立案调查。 据证监会透露， 2026年1月6日，深圳英集芯科技股份有限公司（简称英集芯）在上证E互动平台人为策划"自问自答"，信息披露构成误导性陈述。 近日，证监会已对英集芯立案调查。下一步，将在全面调查的基础上依法处理，切实维护市场健康发展。 事件回顾： 值得一提的是，尽管英集芯发布了公告对相关情况进行了说明，1月7日，英集芯股价仍大幅高开逾9个点，当日报收22.48元/股，上涨4.51%。 英集芯(688209) 02-13 19:34:55 沪 科 融 | 24.42 所属行业: 电子-0.18%> | | | | | | 查看所属板块 > | | --- | --- | --- | --- | --- | --- | --- | | -0.60 -2.40% | | 半导体芯片 | | | 粤港澳大湾区 | | | | | | -0.11% 最相关 | | -0.92% | | | 今 开 | 24.96 最 | | 高 | 25.19 | 成交量 | 12.6万手 | | 昨 收 | 25.02 最 低 | | | 24.42 | 成交额 | 3.14亿 | ...

Core Insights - The article highlights the increasing focus of institutional investors on hard technology breakthroughs and performance certainty for investment opportunities in 2026 [4] Group 1: Institutional Research Trends - In late 2025 to early 2026, institutions conducted research on approximately 1,162 companies, with a total of 30,000 receptions from listed companies across various core industries [3] - The shift in focus from merely gathering data to understanding practical applications indicates a significant change in investment strategies [9] Group 2: Brain-Computer Interface (BCI) Focus - Brain-computer interface technology has emerged as a key area of interest, with companies like Xiangyu Medical, Aipeng Medical, and Meihao Medical frequently hosting inquiries from fund managers [5][6] - Institutions are particularly interested in the depth of collaboration with innovative BCI clients and the feasibility of mass production [7][8] Group 3: AI Computing Power and Applications - The focus on artificial intelligence has shifted from foundational models to the iteration of computing power and practical applications [10] - Companies like Zhongji Xuchuang attracted attention for their 1.6T optical module orders and technology advancements, reflecting a market shift towards evaluating technological iteration speed [10] Group 4: Commercial Aerospace and Semiconductor Focus - Commercial aerospace has gained significant attention, with institutions exploring various segments such as rocket manufacturing and satellite components [17] - In the semiconductor sector, institutions are focused on overcoming technical barriers, with companies like Haimei Information and Huaren Micro receiving extensive inquiries regarding their advanced process products [22][23] - The trend of institutions closely monitoring companies with promising earnings forecasts indicates a more rational investment approach, seeking high-quality targets with core competitiveness [26]

Core Viewpoint - MiniMax has experienced a remarkable stock price surge since its debut on the Hong Kong stock market on January 9, reaching a market capitalization of over HKD 200 billion following the release of its new model M2.5, which has drawn significant attention and investment returns for its backers, particularly miHoYo, which has seen a substantial profit from its early investment [1][3][6]. Group 1: MiniMax's Performance and Market Response - MiniMax's stock price increased by over 13% on February 13, 2023, following the announcement of its new model M2.5, which is said to match the performance of Claude Opus 4.6 [1][2]. - The market responded quickly, with MiniMax's market capitalization exceeding HKD 200 billion [3]. - The company has achieved a unique position in the Chinese large model landscape, having gone from establishment to IPO in just four years [2]. Group 2: Investment and Returns - miHoYo, a gaming company, was one of the angel investors in MiniMax, investing at a post-money valuation of USD 200 million, and has since seen its investment return exceed 100 times [4][6]. - miHoYo's stake in MiniMax increased to 7.34% during subsequent funding rounds, and it currently holds approximately 5.24% of the company post-IPO, translating to a book value of nearly RMB 10 billion [5][6]. - Other notable investors in MiniMax include Hillhouse Capital, IDG Capital, Sequoia China, Alibaba, Tencent, and several others, indicating a broad and significant backing for the company [6]. Group 3: miHoYo's Financial Performance - miHoYo has disclosed that it has paid a total of RMB 15 billion in taxes from 2021 to 2025, reflecting its substantial revenue growth [11]. - In 2021, miHoYo reported a revenue of RMB 27.34 billion and a net profit of RMB 16.145 billion, with tax contributions increasing from RMB 1.8 billion in 2021 to a projected RMB 15 billion by 2025 [11][12]. - The company has made significant investments in various sectors, including technology and gaming, and has been actively involved in the IPO process of other companies [12][14].

Group 1 - The core viewpoint is that Qisheng Technology (603610) has gained market attention due to its stake in Mind Motion, which is venturing into the brain-computer interface (BCI) field with a new digital therapy product for sleep [1] - The launch of the BCI-based sleep therapy product aligns with China's recent breakthroughs in BCI space validation, potentially influencing market sentiment in the short term [1] - The company's main business includes smart home and sensor concepts, with a high proportion of overseas revenue benefiting from the depreciation of the RMB [1] Group 2 - In the past week, Qisheng Technology's stock price has experienced a volatile decline, with a drop of 1.91%, closing at 17.99 yuan [2] - The capital flow indicates a net outflow from major investors, with a net outflow of 5.8377 million yuan on February 13, indicating continuous reduction in holdings [2] - Technically, the stock price is approaching the lower support level of the Bollinger Bands at 17.18 yuan, necessitating attention to whether it can stabilize [2]

Core Viewpoint - The company, 美好医疗, has shown a significant increase in stock price and trading volume, indicating positive market sentiment and potential growth opportunities in the medical device sector [1]. Group 1: Company Performance - 美好医疗's stock rose by 6.57% with a trading volume of 860 million yuan and a turnover rate of 6.75%, leading to a total market capitalization of 19.842 billion yuan [1]. - The company reported a revenue of 1.194 billion yuan for the period from January to September 2025, reflecting a year-on-year growth of 3.28%, while the net profit attributable to shareholders decreased by 19.25% [7][8]. - The company has a significant overseas revenue contribution, accounting for 86.64% of total revenue, benefiting from the depreciation of the yuan [3]. Group 2: Business Operations - 美好医疗 is engaged in the design, development, manufacturing, and sales of precision components and products in the medical device sector, with a focus on home respiratory machine components, cochlear implant components, and pulmonary function instruments [2][7]. - The company is actively collaborating with downstream brain-machine interface clients to facilitate efficient commercialization from laboratory research to mass production, although current revenue from this segment is still small [2]. - 美好医疗 has initiated the construction of automated production lines for weight loss pen orders, expected to be delivered next year [2]. Group 3: Market Dynamics - The company is categorized under the medical device sector, with its main products including home respiratory machine components (59.48% of revenue), consumer electronics components (14.61%), and other medical product components [7]. - The stock has shown signs of accumulation, with an average trading cost of 32.84 yuan, and is approaching a resistance level of 35.00 yuan, indicating potential for upward movement if this level is breached [6].